Pharming's Strategic Pivot: Joenja's Path to Blockbuster and RUCONEST's Modest Rebound
Q2 2026: Revenue dip but cost discipline and a promising CVID/PID readout redefine the growth story.
PHARM.AS · Earnings Call · 2026-07-30
Pharming Group's Q2 2026 earnings call was a tale of two products: RUCONEST, the core on-demand HAE therapy facing its first significant competitive pressure, and Joenja, the up-and-coming leniolisib franchise with ambitions to become a blockbuster. While total revenue declined 3% year-over-year, management used the call to frame a strategic pivot toward Joenja and improved capital discipline. The headline is a $30 million cut to full-year revenue guidance, but offset by a $15 million reduction in operating expense guidance, underscoring a focus on efficiency as the company positions for a data-rich second half.
RUCONEST: Holding the Line in a Shifting Market
RUCONEST revenue fell to $72.3 million in Q2, a 10% decline year-over-year but a 24% sequential increase. The decline is attributed to competitive dynamics, planned withdrawal from international markets, and temporary inventory normalization. Yet the underlying patient metrics are more encouraging. As chief commercial officer Leverne Marsh noted, “the active RUCONEST patient base remains highly resilient at approximately 93% of the prior-year level” — Leverne Marsh, Chief Commercial Officer · 2026-07-30. New patient enrollments rebounded to 84, up from ~50 in Q1 and close to last year's Q2 level. This new enrollment momentum is critical for return to growth in the second half. The company is doubling down on its high burden HAE patients segment, emphasizing RUCONEST's differentiated profile. "We've seen a very clear trend emerging for these high-burden patients that have high-frequency attacks, more severe attacks," Marsh explained in Q&A. This positioning is supported by data showing 97% of attacks resolved in a single dose. The company remains confident that the demand treatment niche will persist despite the new oral competitor.Joenja: The Growth Engine and Pipeline Catalyst
Joenja revenue grew 40% to $17.9 million, with U.S. growth of 31% and international up 150%. The company is executing on multiple fronts: pediatric label expansion with a PDUFA date of October 24, a recent sNDA submission for lower doses, and geographic expansion into Germany (launched July 1) and Japan (expected in August). Fabrice Chouraqui highlighted the broader opportunity: “We see a potentially significant opportunity for leniolisib in broader primary immunodeficiencies, including CVID. This indication represents an addressable patient population up to 40 times larger than APDS.” — Fabrice Chouraqui, Chief Executive Officer · 2026-07-30 The PI3 K Delta pathway is central to this thesis, and the company expects two Phase II studies to read out in Q4. Anurag Relan noted, "We're evaluating lymph node and spleen size, blood cell counts, liver and lung involvement, as well as patient and clinician-reported outcomes." Success could position Joenja as a blockbuster, with potential sales exceeding $1 billion. broader primary immunodeficiencies represent the next leg of growth.Success in this indication could expand the annual sales potential of Joenja to more than $1 billion and establish Joenja as a blockbuster franchise.